Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neovasc Inc.
Coroventis’ CoroFlow software allows Abbott’s PressureWire X to diagnose coronary microvascular dysfunction caused by invisible blockages in the heart’s smallest arteries.
The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.
A new trial will evaluate the feasibility of implanting Medtronic's Intrepid transcatheter mitral valve replacement system through a transfemoral approach after the Intrepid TMVR study showed the feasibility of implanting Intrepid through the transapical approach.
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 28 through Feb. 4, including announcements from Neovasc, NaturalCycles Nordic, and Elekta.
- Medical Devices
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive